| 000 | 02489 a2200697 4500 | ||
|---|---|---|---|
| 005 | 20250516160001.0 | ||
| 264 | 0 | _c20150207 | |
| 008 | 201502s 0 0 eng d | ||
| 022 | _a1776-260X | ||
| 024 | 7 |
_a10.1007/s11523-013-0283-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDi Bartolomeo, M | |
| 245 | 0 | 0 |
_aLack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. _h[electronic resource] |
| 260 |
_bTargeted oncology _cJun 2014 |
||
| 300 |
_a155-62 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aCetuximab |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDNA Mutational Analysis |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGTP Phosphohydrolases _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Proteins _xgenetics |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNuclear Proteins _xgenetics |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins _xgenetics |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xgenetics |
| 650 | 0 | 4 | _aProto-Oncogene Proteins p21(ras) |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aTegafur _xadministration & dosage |
| 650 | 0 | 4 |
_aTranscription Factors _xgenetics |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xgenetics |
| 650 | 0 | 4 |
_aUracil _xadministration & dosage |
| 650 | 0 | 4 |
_aras Proteins _xgenetics |
| 700 | 1 | _aPietrantonio, F | |
| 700 | 1 | _aPerrone, F | |
| 700 | 1 | _aDotti, K F | |
| 700 | 1 | _aLampis, A | |
| 700 | 1 | _aBertan, C | |
| 700 | 1 | _aBeretta, E | |
| 700 | 1 | _aRimassa, L | |
| 700 | 1 | _aCarbone, C | |
| 700 | 1 | _aBiondani, P | |
| 700 | 1 | _aPassalacqua, R | |
| 700 | 1 | _aPilotti, S | |
| 700 | 1 | _aBajetta, E | |
| 773 | 0 |
_tTargeted oncology _gvol. 9 _gno. 2 _gp. 155-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11523-013-0283-8 _zAvailable from publisher's website |
| 999 |
_c22886512 _d22886512 |
||